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BRIEF REPORT
Lost in Translation: No Effect of a High-Profile Publication
on the Concomitant Use of Interacting Drugs
Emily K. Acton1,2, Charles E. Leonard2,3, Warren B. Bilker2,3, Shobha Phansalkar4 and Sean Hennessy2,3,5,∗
We sought to assess whether a high-profile publication that demonstrated serious clinical consequences of specific drug-
drug interactions (DDIs) reduced the concomitant use of those drugs. We conducted a quasi-experimental study using 2000–
2008 prescription claims from a commercial health insurer to examine trends in the dispensing of the interacting drug pairs
(angiotensin-converting enzyme inhibitors[ACEI]+ potassium-sparing diuretic, digoxin+ clarithromycin, and glyburide+ cot-
rimoxazole) and control drug pairs previously reported in a top-tier general medicine journal. We examined prepublication and
postpublication dispensing trends using Poisson regression. ACEI + potassium-sparing diuretic use did not differ postpub-
lication vs. prepublication (P = 0.11). Digoxin + clarithromycin use decreased minimally postpublication vs. prepublication
(relative rate = 0.9996: 95% confidence interval [CI] = 0.9993–0.9998). Glyburide + cotrimoxazole use increased minimally
postpublication vs. prepublication (relative rate= 1.0220; 95% CI = 1.0187–1.0254). Therefore, the high-profile DDI publication
had minimal to no measurable effect in reducing the concomitant use of the interacting drugs studied. We believe that better
strategies are needed to translate knowledge about DDIs into clinical practice.
Clin Transl Sci (2017) 10, 426–430; doi:10.1111/cts.12494; published online on 28 July 2017.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ DDIs are a major cause of avoidable morbidity and
mortality, and their ongoing frequency suggests a lack of
translation of research findings into clinical practice.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ We sought to examine the impact of a high-profile DDI
publication on trends in the concomitant use of the inter-
acting drug pairs analyzed.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✔ A high-impact DDI publication had minimal to no effect
on the concomitant use of the adversely interacting drug
pairs that it analyzed.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE
✔ These findings may emphasize the need for increased
focus on improving the overall quality and signal-to-noise
ratio in DDI knowledge bases.
Drug-drug interactions (DDIs) are a major cause of avoid-
able morbidity and mortality, contributing to 1.1% of hospital
admissions and 0.1% of outpatient or emergency visits to the
hospital.1 Major contributory factors in the high frequency of
adverse DDIs are the significant discordance between DDI
knowledge bases2 and the estimated 90% of DDI alerts that
are overridden.3 These findings may suggest a problem with
translating research about DDIs into clinical practice. How-
ever, this has proven to be a complex problem to study, given
the ongoing changes to clinical practice combined with the
rapid rate of evolution of DDI knowledge bases and comput-
erized clinical decision support (CDS) systems.2,4 To explore
this problem, we selected a single, high-impact publication
by Juurlink et al.,5 which reported three sets of DDIs that
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had been previously identified but not confirmed in con-
trolled studies of health outcomes (glyburide + cotrimoxa-
zole; digoxin + clarithromycin; and angiotensin-converting
enzyme inhibitors (ACEI) + potassium-sparing diuretic) to
be strongly associated (odds ratios = 6.6–20.3) with hos-
pitalization for adverse drug events.5,6 We sought to deter-
mine if this large-scale epidemiological study demonstrating
the substantial risks posed by these interacting drug pairs
affected the frequency of their concomitant use.
MATERIALS AND METHODS
We conducted a quasi-experimental study using 2000–
2008 prescription claims from a large US commercial health
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Figure 1 Overall trends in the concomitant use of target* vs. control** drug pairs. *Target drug pairs refer to the interacting drug pairs,
or the object-precipitant drug pairs, with the object drug being defined as the affected drug (i.e., glyburide, digoxin, and ACEI), and the
precipitant drug being defined as the affecter drug (i.e., cotrimoxazole, clarithromycin, potassium-sparing diuretic).7 **Control drug pairs
refer to the control, noninteracting drug pairs.
insurer (Clinformatics Data Mart, OptumInsight, Eden Prairie,
MN). We examined discontinuity between prepublication and
postpublication trends in the frequency of concomitant use
of the following target drug pairs reported by Juurlink et al.5
to be strongly associated with hospitalization for adverse
drug events: ACEI + potassium-sparing diuretic; digoxin
+ clarithromycin; and glyburide + cotrimoxazole. For each
DDI, the object drug was defined as the affected drug (i.e.,
ACEI, digoxin, and glyburide), and the precipitant drug was
defined as the affecter drug (i.e., potassium-sparing diuretic,
clarithromycin, and cotrimoxazole).7 As control pairs, we
examined trends in the object drugs’ concomitant use with
the noninteracting control drugs used in the Juurlink et al.5
(2003) publication: ACEI + indapamide; digoxin + cefurox-
ime; and glyburide + amoxicillin. These control pairs are not
believed to interact.
We defined concomitant use by assessing overlap in the
dispensing of typical duration of use of prescriptions for
each object-precipitant or control drug pair. We assumed that
antibiotic prescriptions lasted for 10 days and that nonan-
tibiotic prescriptions lasted for 30 days. The prepublication
period was May 2000–March 2003, ending when the Juurlink
et al.5 paper was published. We assumed that any effects of
publication on prescribing would take at least 6 months to
occur, so we excluded April–September 2003. The postpub-
lication period was October 2003–December 2008. We used
Poisson regression to assess the prepost change in slope
for the target vs. control pairs, an interaction between time
period and group, examined collectively and individually.
This study was approved by the University of Pennsylvania
Institutional Review Board.
RESULTS
Utilizing prescription claims from a large US commercial
health insurer obtained between 2000 and 2008, we exam-
ined discontinuity in trends between prepublication and post-
publication frequency of concomitant use of the interact-
ing drug pairs analyzed in Juurlink et al.5 For each of these
interacting drug pairs, the object drug is defined as the
affected drug (i.e., ACEI, digoxin, or glyburide), and the pre-
cipitant drug is defined as the affecter drug (i.e., potassium-
sparing diuretic, clarithromycin, or cotrimoxazole).7 Figure 17
presents the collective trends in the use of target (i.e., inter-
acting and object-precipitant) and control (i.e., noninteract-
ing) drug pairs. Visually, the target and control pairs demon-
strated similar trends of use, and there was no statistically
significant difference in postpublication vs. prepublication
trends between the combination of all target vs. all control
drug pairs (P = 0.24). Figure 2 presents trends for individual
drug pairs. Publication was not accompanied by a change in
the use of ACEI + potassium-sparing diuretic vs. the control
pair, ACEI + indapamide (P = 0.11). Publication was asso-
ciated with a 0.04% reduction in the use of digoxin + clar-
ithromycin vs. the control pair, digoxin + cefuroxime (relative
rate = 0.9996; 95% CI = 0.9993–0.9998), although that rel-
ative reduction seems to be due to an increase in postpub-
lication use of digoxin + cefuroxime rather than a change in
the declining prepublication trend in digoxin+ clarithromycin
(Figure 2b). Publication was paradoxically associated with a
2.20% increase in use of glyburide + cotrimoxazole vs. the
control pair, glyburide + amoxicillin (relative rate = 1.0220;
95% CI = 1.0187–1.0254).
www.cts-journal.com
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Figure 2 Pair-specific trends in the concomitant use of target vs. control drug pairs. (a) Angiotensin-converting enzyme inhibitors (ACEI)+
potassium-sparing diuretic and ACEI + indapamide: ACEI + potassium-sparing diuretic did not have a significant change in concomitant
use in the prepublication vs. postpublication periods (P = 0.11). (b) Digoxin + clarithromycin and digoxin + cefuroxime: digoxin + clar-
ithromycin were less likely to be used concomitantly in the postpublication vs. prepublication period (P < 0.001; relative rate = 0.9996:
95% confidence interval [CI] = 0.9993–0.9998). (c) Glyburide + cotrimoxazole and glyburide + amoxicillin: glyburide + cotrimoxazole
were more likely to be used concomitantly in the postpublication vs. prepublication period (P < 0.001; relative rate = 1.0220; 95% CI =
1.0187–1.0254).
DISCUSSION
We found that publication of a high-profile epidemiologic
study demonstrating serious clinical consequences of three
target DDIs had minimal to no measurable effect on con-
comitant use of the hazardous drug pairs. The publication
had no apparent overall effect on the combination of the
three drug pairs’ concomitant usage trends, and no appar-
ent effect on the concomitant use of ACEI + potassium-
sparing diuretic. Moreover, we found the concomitant use of
glyburide + cotrimoxazole increased by 2.2% following pub-
lication. In fact, the only evidence we found suggesting the
Juurlink et al.5 publication had any impact on clinical pre-
scribing practices was an extremely modest 0.04% reduc-
tion in the trend of digoxin + clarithromycin concomitant
use following publication. This apparent reduction seemed
to be due to an increase in postpublication use of digoxin +
cefuroxime rather than a change in the declining prepublica-
tion trend in digoxin + clarithromycin.
Strengths of this study include that it examined a large,
representative US commercial health insurance database,
used objective measurements of concomitancy, and tracked
longitudinal trends in concomitant use to estimate the impact
of the published article. We selected the Juurlink et al.5 pub-
lication as our focus because it explored DDIs among com-
monly utilized medications, and because of its high visibil-
ity, with publication in a top-tier journal, 684 citations (by
22 June 2017), and an Altmetric score in the top 5% of all
scored articles. It is important to acknowledge that, in many
cases, it may not be appropriate to expect a single high-
visibility study to impact clinical practice. At the time of the
Juurlink et al.5 publication (as well as prior to May 2000, the
Clinical and Translational Science
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start of our prepublication trend analysis), the potential for
all three drug pairs to interact was already reported in prod-
uct labels,6 although no controlled studies had yet confirmed
the existence or magnitude of the health risks associated
with their concomitant administration. Given that prescriber
knowledge of DDIs during the study period was shown to be
poor,8 we had hoped that a high-profile paper demonstrating
and quantifying large-magnitude, serious risks would have
a measurable impact on the concomitant use of the inter-
acting drugs. Although it is possible that some prescribers
managed the risks by monitoring serum potassium concen-
tration, serum digoxin concentration, or serum glucose, two
of the three interactions involve antibiotics that are typically
given for a short course, making it seemingly less likely that
enhanced monitoring over a few days would have been an
effective strategy to manage the risks of these DDIs.
What could explain health care’s apparent failure to trans-
late the results from the Juurlink et al.5 publication into prac-
tice? Given the enormous number of drug combinations that
must be scrutinized to avoid DDIs in clinical practice, and
prescribers’ poor knowledge of DDIs,8 computerized CDS
systems are relied upon heavily. During the 2000–2008 study
period, CDS systems with DDI alerts were not universally
available in the United States, particularly among smaller
hospitals and office practices.9 Moreover, even when CDS
was available, many other barriers to use have been found,
including the lack of any of the following: available hard-
ware, sufficient technical support, integration of the sys-
tem into clinical workflow, timeliness of the clinical mes-
sages provided, clear articulation of the system’s benefits
in patient care, and minimizing perceived threats to profes-
sional autonomy.10 These findings are further supported by
survey data obtained in 2005 suggesting that the primary
source of alerts about potential DDIs for many prescribers
were pharmacists, rather than CDS systems.8 Further, for DDI
alerting, these barriers are compounded by the proprietary
knowledge bases that screen for DDIs having an unknown
time lag for incorporating new findings, being incomplete,11
mostly disagreeing with one another,2 and being shown to
“generate excessive number[s] of alerts, many of which are
clinically unhelpful.”12 This excessive number of alerts results
in alert fatigue and attendant reflexive overriding of alerts,
contributing to the 90% of DDI alerts that are overridden.3
Translating knowledge from studies of the health effects of
DDIs into clinical practice may, therefore, require improving
the overall quality and signal-to-noise ratio of DDI knowledge
bases.
Our study has limitations. The database used only
recorded prescriptions dispensed in the outpatient setting.
Thus, we cannot draw conclusions about the impact of the
publication by Juurlink et al.5 on: (a) ambulatory prescrip-
tions that were never filled (i.e., primary nonadherence); or
(b) inpatient dispensing. Additionally, it is possible that our
study underestimated the clinical impact of the publication
by focusing on concomitant dispensing trends rather than
DDI-related adverse events. It is also noteworthy that the
Juurlink et al.5 paper focused exclusively on the occurrence
of DDIs in people 66 years of age or older, as necessitated by
their use of the Ontario Drug Benefit Program claims. As our
focus was on the impact of this paper, we elected to more
broadly examine the overall trends in concomitant prescrip-
tion regardless of recipient ages, as we felt this publication
would have had impact outside of its analyzed age range.
With the rapid pace of CDS and knowledge base
evolution,2,4 and potential differences in CDS availability
internationally,8 further research is needed to understand the
generalizability of our conclusions. Also, we elected to utilize
the same control drug pairs as Juurlink et al.,5 because there
is no literature to suggest interactions between the control
drug pairs. However, selecting optimal controls for this sort
of study is inherently challenging, given that drug trends over
time can be difficult to predict or even fully account for in ret-
rospect potentially introducing bias into our findings. Finally,
althoughwe are aware of nomajor publications or large-scale
health practice changes that would have directly affected
the frequency of co-administration of the drugs studied, it
is possible there may have been other literature or clinical
practice changes that impeded the translation of the Juurlink
et al.5 publication into clinical practice. For example, a subse-
quent study by Juurlink et al.13 (2004), reported that when the
randomized aldactone evaluation study (1999) demonstrated
that spironolactone use reduces morbidity and mortality in
patients with severe heart failure,14 an increase in adverse
events associated with the concomitant use of aldosterone
and ACEIs was observed. These limitations present impor-
tant areas for future studies to explore.
Our study found that a high-impact publication demon-
strating substantial risks associated with DDIs hadminimal to
no effect on the concomitant use of the adversely interacting
drug pairs that it analyzed. This suggests a lack of transla-
tion of research findings into clinical practice. A crucial step
in reducing drug-related adverse events may be to improve
the overall quality and signal-to-noise ratio in DDI knowledge
bases.
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